Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05526911 · ClinicalTrials.gov registry record · Phase 1

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

A Phase 1 study of Tuberculosis and Pulmonary Disease, sponsored by Global Alliance for TB Drug Development.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target
1
Study location

NCT05526911: Completed Phase 1 study of Tuberculosis and Pulmonary Disease, sponsored by Global Alliance for TB Drug Development.

NCT05526911 is a Phase 1 study of Tuberculosis and Pulmonary Disease that has completed, run by Global Alliance for TB Drug Development. The registered enrollment target is 28 participants, below the 933-participant average among 29 other Tuberculosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05526911, a Phase 1 study of Tuberculosis and Pulmonary Disease, has completed, sponsored by Global Alliance for TB Drug Development.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects

Primary Outcome

Geometric mean and range of midazolam's area under the (plasma concentration vs. time) curve when co-administered with TBAJ-876 versus when administered alone.

Interventions

  • DRUG Midazolam
  • DRUG Digoxin
  • DRUG TBAJ-876

Study Locations (1)

New Jersey

  • TKL Research, Inc. - Fair Lawn

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2022-06-30
Est. Completion 2022-09-26
Phase Phase 1

What the finished NCT05526911 record still lists

NCT05526911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 933-participant average among 29 other Tuberculosis trials with a reported enrollment target (97% lower).

The record links to 7 conditions, with Tuberculosis appearing as the primary indexed condition, and to 3 interventions - of which Midazolam is the first listed.

NCT05526911 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT05526911 about?

NCT05526911 is a clinical study titled "A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults". A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects

What is the current status of trial NCT05526911?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2022-06-30. Estimated completion is 2022-09-26.

What conditions does trial NCT05526911 study?

This clinical trial studies the following conditions: Tuberculosis, Pulmonary Disease, Tuberculosis, Pulmonary, Multi-drug Resistant Tuberculosis, Drug Sensitive Tuberculosis.

What interventions are being tested in trial NCT05526911?

The interventions under investigation include: Midazolam (DRUG), Digoxin (DRUG), TBAJ-876 (DRUG).

Who is sponsoring clinical trial NCT05526911?

This trial is sponsored by Global Alliance for TB Drug Development, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05526911 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tuberculosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05526911's enrollment target sits among peer trials

28 27th of 29 higher than 2 of 29 other Tuberculosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tuberculosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05526911, the US trial registry maintained by the National Library of Medicine. NCT05526911 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.